These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 8770849)

  • 21. [Thrombolytic agents, urokinase, tissue-type plasminogen activator and pro-urokinase--their routes of administration and dosage: comparison between intracoronary thrombolysis and intravenous coronary thrombolysis].
    Motomiya T
    Nihon Rinsho; 2003 Apr; 61 Suppl 4():441-5. PubMed ID: 12735012
    [No Abstract]   [Full Text] [Related]  

  • 22. Enhancement of the thrombolytic efficacy of prourokinase by lys-plasminogen in a dog model of arterial thrombosis.
    Badylak SF; Voytik SL; Henkin J; Burke SE; Sasahara AA; Simmons A
    Thromb Res; 1991 May; 62(3):115-26. PubMed ID: 1716378
    [TBL] [Abstract][Full Text] [Related]  

  • 23. More rapid, complete, and stable coronary thrombolysis with bolus administration of reteplase compared with alteplase infusion in acute myocardial infarction. RAPID Investigators.
    Smalling RW; Bode C; Kalbfleisch J; Sen S; Limbourg P; Forycki F; Habib G; Feldman R; Hohnloser S; Seals A
    Circulation; 1995 Jun; 91(11):2725-32. PubMed ID: 7758177
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Site-specific intracoronary thrombolysis with urokinase-coated hydrogel balloons: acute and follow-up studies in 95 patients.
    Glazier JJ; Hirst JA; Kiernan FJ; Fram DB; Eldin AM; Primiano CA; Mitchel JF; McKay RG
    Cathet Cardiovasc Diagn; 1997 Jul; 41(3):246-53. PubMed ID: 9213022
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Saruplase is a safe and effective thrombolytic agent; observations in 1,698 patients: results of the PASS study. Practical Applications of Saruplase Study.
    Vermeer F; Bösl I; Meyer J; Bär F; Charbonnier B; Windeler J; Barth H
    J Thromb Thrombolysis; 1999 Aug; 8(2):143-50. PubMed ID: 10436145
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of saruplase and alteplase in acute myocardial infarction. SESAM Study Group. The Study in Europe with Saruplase and Alteplase in Myocardial Infarction.
    Bär FW; Meyer J; Vermeer F; Michels R; Charbonnier B; Haerten K; Spiecker M; Macaya C; Hanssen M; Heras M; Boland JP; Morice MC; Dunn FG; Uebis R; Hamm C; Ayzenberg O; Strupp G; Withagen AJ; Klein W; Windeler J; Hopkins G; Barth H; von Fisenne MJ
    Am J Cardiol; 1997 Mar; 79(6):727-32. PubMed ID: 9070549
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Patency trials with reteplase (r-PA): what do they tell us?
    Bode C; Nordt TK; Peter K; Smalling RW; Runge MS; Kübler W
    Am J Cardiol; 1996 Dec; 78(12A):16-9. PubMed ID: 8990406
    [TBL] [Abstract][Full Text] [Related]  

  • 28. ESPRIT: a European study of the prevention of reocclusion after initial thrombolysis with duteplase in acute myocardial infarction.
    Malcolm AD; Keltai M; Walsh MJ
    Eur Heart J; 1996 Oct; 17(10):1522-31. PubMed ID: 8909909
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Intravenous infusion of recombinant tissue-type plasminogen activator (rt-PA) and urokinase in acute myocardial infarct: intermediate results of the G.A.U.S. study (German Activator Urokinase Study)].
    Neuhaus KL; Tebbe U; Gottwik M; Weber MA; Feuerer W; Niederer W; Haerer W; Praetorius F; Grosser KD; Huhmann W
    Klin Wochenschr; 1988; 66 Suppl 12():102-8. PubMed ID: 3126339
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sequential combination thrombolytic therapy for acute myocardial infarction: results of the Pro-Urokinase and t-PA Enhancement of Thrombolysis (PATENT) Trial.
    Zarich SW; Kowalchuk GJ; Weaver WD; Loscalzo J; Sassower M; Manzo K; Byrnes C; Muller JE; Gurewich V
    J Am Coll Cardiol; 1995 Aug; 26(2):374-9. PubMed ID: 7608437
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Intravenous thrombolytic therapy with a combination of single-chain urokinase-type plasminogen activator and recombinant tissue-type plasminogen activator in acute myocardial infarction.
    Bode C; Schuler G; Nordt T; Schönermark S; Baumann H; Richardt G; Dietz R; Gurewich V; Kübler W
    Circulation; 1990 Mar; 81(3):907-13. PubMed ID: 2106403
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rate of fibrinogen breakdown related to coronary patency and bleeding complications in patients with thrombolysis in acute myocardial infarction--results from the PRIMI trial.
    Ostermann H; Schmitz-Huebner U; Windeler J; Bär F; Meyer J; van de Loo J
    Eur Heart J; 1992 Sep; 13(9):1225-32. PubMed ID: 1396833
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Accelerated plasminogen activator dose regimens for coronary thrombolysis. The TAMI-7 Study Group.
    Wall TC; Califf RM; George BS; Ellis SG; Samaha JK; Kereiakes DJ; Worley SJ; Sigmon K; Topol EJ
    J Am Coll Cardiol; 1992 Mar; 19(3):482-9. PubMed ID: 1537998
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Thrombolysis: A Critical First-Line Therapy with an Unfulfilled Potential.
    Gurewich V
    Am J Med; 2016 Jun; 129(6):573-5. PubMed ID: 26714208
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Coronary reperfusion studies with pro-urokinase in acute myocardial infarction: evidence for synergism of low dose urokinase.
    Kasper W; Hohnloser SH; Engler H; Meinertz T; Wilkens J; Roth E; Lang K; Limbourg P; Just H
    J Am Coll Cardiol; 1990 Sep; 16(3):733-8. PubMed ID: 2117622
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Coronary thrombolysis by intravenous infusion of recombinant single chain urokinase-type plasminogen activator or recombinant urokinase in baboons: effect on regional blood flow, infarct size and hemostasis.
    Flameng W; Vanhaecke J; Stump DC; Van de Werf F; Holmes W; Guenzler WA; Flohe L; Collen D
    J Am Coll Cardiol; 1986 Jul; 8(1):118-24. PubMed ID: 3086416
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Thrombolysis vs. bleeding from hemostatic sites by a prourokinase mutant compared with tissue plasminogen activator.
    Gurewich V; Pannell R; Simmons-Byrd A; Sarmientos P; Liu JN; Badylak SF
    J Thromb Haemost; 2006 Jul; 4(7):1559-65. PubMed ID: 16839354
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Coronary thrombolytic agents and their characteristics].
    Yoshinaga M; Kambara H
    Nihon Rinsho; 1994 Jul; 52 Suppl(Pt 1):775-81. PubMed ID: 12436615
    [No Abstract]   [Full Text] [Related]  

  • 39. Dose-related efficacy and bleeding complications of double-chain tissue plasminogen activator in acute myocardial infarction. The Wellcome Tissue Plasminogen Activator Study Group.
    Turi ZG; Goldberg S; LittleJohn JK; Vander Ark C; Shadoff N; Karlsberg R; Williams J; Butman S; Stadius ML; Wise K
    Am J Cardiol; 1993 May; 71(12):1009-14. PubMed ID: 8475860
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Influence of time to treatment on early infarct-related artery patency after different thrombolytic regimens. ALKK-Study Group.
    Zeymer U; Tebbe U; Essen Rv; Haarmann W; Neuhaus KL
    Am Heart J; 1999 Jan; 137(1):34-8. PubMed ID: 9878934
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.